Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China. more
Time Frame | ZLAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.38% | -0.94% | -2.6% |
1-Month Return | -5.52% | -5.08% | -1.08% |
3-Month Return | 28.09% | -10.62% | 3.45% |
6-Month Return | 41.55% | -6.18% | 8.57% |
1-Year Return | 2.79% | 1.98% | 24.3% |
3-Year Return | -59.69% | -0.93% | 25.58% |
5-Year Return | -32.3% | 33.84% | 84.07% |
10-Year Return | -4.98% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 12.98M | 48.96M | 144.31M | 215.04M | 266.72M | [{"date":"2019-12-31","value":4.87,"profit":true},{"date":"2020-12-31","value":18.36,"profit":true},{"date":"2021-12-31","value":54.11,"profit":true},{"date":"2022-12-31","value":80.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 3.75M | 16.74M | 52.24M | 74.02M | 95.82M | [{"date":"2019-12-31","value":3.91,"profit":true},{"date":"2020-12-31","value":17.47,"profit":true},{"date":"2021-12-31","value":54.52,"profit":true},{"date":"2022-12-31","value":77.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 9.24M | 32.22M | 92.07M | 141.02M | 170.90M | [{"date":"2019-12-31","value":5.4,"profit":true},{"date":"2020-12-31","value":18.85,"profit":true},{"date":"2021-12-31","value":53.87,"profit":true},{"date":"2022-12-31","value":82.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 71.13% | 65.82% | 63.80% | 65.58% | 64.08% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.53,"profit":true},{"date":"2021-12-31","value":89.7,"profit":true},{"date":"2022-12-31","value":92.2,"profit":true},{"date":"2023-12-31","value":90.08,"profit":true}] |
Operating Expenses | 212.43M | 334.02M | 792.14M | 545.38M | 547.48M | [{"date":"2019-12-31","value":26.82,"profit":true},{"date":"2020-12-31","value":42.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.85,"profit":true},{"date":"2023-12-31","value":69.11,"profit":true}] |
Operating Income | (203.20M) | (301.80M) | (700.06M) | (404.36M) | (366.57M) | [{"date":"2019-12-31","value":-20319593900,"profit":false},{"date":"2020-12-31","value":-30180100000,"profit":false},{"date":"2021-12-31","value":-70006400000,"profit":false},{"date":"2022-12-31","value":-40435700000,"profit":false},{"date":"2023-12-31","value":-36657300000,"profit":false}] |
Total Non-Operating Income/Expense | 16.82M | 38.95M | (1.16M) | (24.13M) | 70.79M | [{"date":"2019-12-31","value":23.75,"profit":true},{"date":"2020-12-31","value":55.03,"profit":true},{"date":"2021-12-31","value":-1.64,"profit":false},{"date":"2022-12-31","value":-34.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (194.32M) | (267.79M) | (703.41M) | (443.06M) | (334.62M) | [{"date":"2019-12-31","value":-19431892400,"profit":false},{"date":"2020-12-31","value":-26778600000,"profit":false},{"date":"2021-12-31","value":-70341400000,"profit":false},{"date":"2022-12-31","value":-44306500000,"profit":false},{"date":"2023-12-31","value":-33462000000,"profit":false}] |
Income Taxes | (10.95M) | 30.38M | (10.97M) | 38.93M | 38.93M | [{"date":"2019-12-31","value":-28.14,"profit":false},{"date":"2020-12-31","value":78.03,"profit":true},{"date":"2021-12-31","value":-28.18,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (183.37M) | (298.16M) | (692.44M) | (481.99M) | (373.55M) | [{"date":"2019-12-31","value":-18336589400,"profit":false},{"date":"2020-12-31","value":-29816200000,"profit":false},{"date":"2021-12-31","value":-69244400000,"profit":false},{"date":"2022-12-31","value":-48199400000,"profit":false},{"date":"2023-12-31","value":-37354900000,"profit":false}] |
Income From Continuous Operations | (195.07M) | (268.90M) | (704.47M) | (443.29M) | (300.96M) | [{"date":"2019-12-31","value":-19507100000,"profit":false},{"date":"2020-12-31","value":-26890500000,"profit":false},{"date":"2021-12-31","value":-70447100000,"profit":false},{"date":"2022-12-31","value":-44328600000,"profit":false},{"date":"2023-12-31","value":-30096000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (183.37M) | (298.16M) | (692.44M) | (481.99M) | (334.62M) | [{"date":"2019-12-31","value":-18336589400,"profit":false},{"date":"2020-12-31","value":-29816200000,"profit":false},{"date":"2021-12-31","value":-69244400000,"profit":false},{"date":"2022-12-31","value":-48199400000,"profit":false},{"date":"2023-12-31","value":-33462000000,"profit":false}] |
EPS (Diluted) | (2.62) | (2.78) | (7.58) | (4.67) | (3.47) | [{"date":"2019-12-31","value":-261.87,"profit":false},{"date":"2020-12-31","value":-277.62,"profit":false},{"date":"2021-12-31","value":-758,"profit":false},{"date":"2022-12-31","value":-467,"profit":false},{"date":"2023-12-31","value":-347,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ZLAB | |
---|---|
Cash Ratio | 2.15 |
Current Ratio | 3.01 |
Quick Ratio | 2.87 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ZLAB | |
---|---|
ROA (LTM) | -20.83% |
ROE (LTM) | -34.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ZLAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.32 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.68 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ZLAB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.13 |
P/B | 4.36 |
Price/FCF | NM |
EV/R | 6.74 |
EV/Ebitda | NM |
Zai Lab Ltd (ZLAB) share price today is $26.54
Yes, Indians can buy shares of Zai Lab Ltd (ZLAB) on Vested. To buy Zai Lab Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZLAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Zai Lab Ltd (ZLAB) via the Vested app. You can start investing in Zai Lab Ltd (ZLAB) with a minimum investment of $1.
You can invest in shares of Zai Lab Ltd (ZLAB) via Vested in three simple steps:
The 52-week high price of Zai Lab Ltd (ZLAB) is $36.6. The 52-week low price of Zai Lab Ltd (ZLAB) is $13.48.
The price-to-earnings (P/E) ratio of Zai Lab Ltd (ZLAB) is
The price-to-book (P/B) ratio of Zai Lab Ltd (ZLAB) is 4.36
The dividend yield of Zai Lab Ltd (ZLAB) is 0.00%
The market capitalization of Zai Lab Ltd (ZLAB) is $2.91B
The stock symbol (or ticker) of Zai Lab Ltd is ZLAB